Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth
Update your Virtual Booth on PharmaCompass, ask us
About
CPhI India 2024CPhI India 2024
Not Confirmed
Not Confirmed
26-28 November, 2024
BioFlorida ConferenceBioFlorida Conference
Not Confirmed
Not Confirmed
18-20 November, 2024
Not Confirmed
Not Confirmed
19-21 November, 2024
List your booth number for exhibitions, ask us
CONTACT DETAILS
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Events
Webinars & Exhibitions
CPhI India 2024CPhI India 2024
Industry Trade Show
Not Confirmed
26-28 November, 2024
BioFlorida ConferenceBioFlorida Conference
Industry Trade Show
Not Confirmed
18-20 November, 2024
Industry Trade Show
Not Confirmed
19-21 November, 2024
Digital content
INTERVIEW #SpeakPharma
[Sponsored by another company]https://www.pharmacompass.com/speak-pharma/lgm-pharma-has-made-significant-strides-in-meeting-the-evolving-needs-of-its-clients
VLOG #PharmaReel
[Sponsored by another company]DATA COMPILATION #PharmaFlow
[Sponsored by another company]https://www.pharmacompass.com/radio-compass-blog/chinese-fda-registered-generic-facilities-gain-steam-india-maintains-lead-with-396-facilities
18 Nov 2024
// FIERCE BIOTECH
https://www.fiercebiotech.com/biotech/incytes-750m-buyout-rocked-pause-key-trial-asset-cull
07 Nov 2024
// BUSINESSWIRE
05 Nov 2024
// FIERCE PHARMA
https://www.fiercepharma.com/pharma/incyte-blocks-launch-sun-pharmas-jak-inhibitor-newcomer-leqselvi-alopecia
30 Oct 2024
// BUSINESSWIRE
29 Oct 2024
// BUSINESSWIRE
29 Oct 2024
// REUTERS
https://www.reuters.com/business/healthcare-pharmaceuticals/incyte-raises-2024-sales-forecast-top-selling-drug-jakafi-2024-10-29/
Details:
INCB123667 is a novel, potent and selective oral small molecule inhibitor of CDK2, being investigated in Patients with Advanced Solid Tumors, Notably Ovarian Cancer.
Lead Product(s): INCB123667
Therapeutic Area: Oncology Brand Name: INCB123667
Study Phase: Phase IProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 14, 2024
Incyte’s CDK2 Inhibitor INCB123667 Shows Clinical Activity in Advanced Solid Tumors
Details : INCB123667 is a novel, potent and selective oral small molecule inhibitor of CDK2, being investigated in Patients with Advanced Solid Tumors, Notably Ovarian Cancer.
Brand Name : INCB123667
Molecule Type : Small molecule
Upfront Cash : Not Applicable
September 14, 2024
Details:
Monjuvi (tafasitamab) is a humanized Fc-modified cytolytic CD19-targeting antibody, which is being evaluated in combination with lenalidomide & rituximab for the treatment of R/R follicular lymphoma.
Lead Product(s): Tafasitamab,Rituximab,Lenalidomide
Therapeutic Area: Oncology Brand Name: Monjuvi
Study Phase: Phase IIIProduct Type: Large molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 15, 2024
Lead Product(s) : Tafasitamab,Rituximab,Lenalidomide
Therapeutic Area : Oncology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Incyte Announces Positive Results from Tafasitamab (Monjuvi) Study in Follicular Lymphoma
Details : Monjuvi (tafasitamab) is a humanized Fc-modified cytolytic CD19-targeting antibody, which is being evaluated in combination with lenalidomide & rituximab for the treatment of R/R follicular lymphoma.
Brand Name : Monjuvi
Molecule Type : Large molecule
Upfront Cash : Not Applicable
August 15, 2024
Details:
Niktimvo (axatilimab) is an investigational monoclonal antibody that targets CSF-1R. It is approved for the treatment of chronic graft-versus-host disease.
Lead Product(s): Axatilimab
Therapeutic Area: Immunology Brand Name: Niktimvo
Study Phase: ApprovedProduct Type: Large molecule
Sponsor: Syndax Pharmaceuticals
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 14, 2024
Lead Product(s) : Axatilimab
Therapeutic Area : Immunology
Highest Development Status : Approved
Partner/Sponsor/Collaborator : Syndax Pharmaceuticals
Deal Size : Not Applicable
Deal Type : Not Applicable
Incyte & Syndax Receive FDA Approval for Niktimvo for Chronic Graft-Versus-Host Disease
Details : Niktimvo (axatilimab) is an investigational monoclonal antibody that targets CSF-1R. It is approved for the treatment of chronic graft-versus-host disease.
Brand Name : Niktimvo
Molecule Type : Large molecule
Upfront Cash : Not Applicable
August 14, 2024
Details:
Under the license agreement, MacroGenics will focus on the development of Zynyz (retifanlimab), which is being evaluated in the late-stage trial studies for treating Squamous Cell Anal Carcinoma.
Lead Product(s): Retifanlimab,Paclitaxel,Carboplatin
Therapeutic Area: Oncology Brand Name: Zynyz
Study Phase: Phase IIIProduct Type: Large molecule
Recipient: MacroGenics
Deal Size: $905.0 million Upfront Cash: $150.0 million
Deal Type: Licensing Agreement July 30, 2024
Lead Product(s) : Retifanlimab,Paclitaxel,Carboplatin
Therapeutic Area : Oncology
Highest Development Status : Phase III
Recipient : MacroGenics
Deal Size : $905.0 million
Deal Type : Licensing Agreement
MacroGenics Achieves $100M in Milestones from Retifanlimab Collaboration with Incyte
Details : Under the license agreement, MacroGenics will focus on the development of Zynyz (retifanlimab), which is being evaluated in the late-stage trial studies for treating Squamous Cell Anal Carcinoma.
Brand Name : Zynyz
Molecule Type : Large molecule
Upfront Cash : $150.0 million
July 30, 2024
Details:
Incyte will gain access to Escient's pipeline, which includes EP262, a potent, highly selective once-daily small molecule antagonist of MRGPRX2, currently undergoing evaluation for atopic dermatitis.
Lead Product(s): EP262
Therapeutic Area: Dermatology Brand Name: EP262
Study Phase: Phase IIProduct Type: Small molecule
Recipient: Escient Pharmaceuticals
Deal Size: $750.0 million Upfront Cash: Undisclosed
Deal Type: Acquisition May 30, 2024
Lead Product(s) : EP262
Therapeutic Area : Dermatology
Highest Development Status : Phase II
Recipient : Escient Pharmaceuticals
Deal Size : $750.0 million
Deal Type : Acquisition
Incyte Completes Acquisition of Escient Pharmaceuticals
Details : Incyte will gain access to Escient's pipeline, which includes EP262, a potent, highly selective once-daily small molecule antagonist of MRGPRX2, currently undergoing evaluation for atopic dermatitis.
Brand Name : EP262
Molecule Type : Small molecule
Upfront Cash : Undisclosed
May 30, 2024
Details:
Incyte gains access to Escient's pipeline, including EP262, a selective small molecule antagonist of MRGPRX2 for atopic dermatitis.
Lead Product(s): EP262
Therapeutic Area: Dermatology Brand Name: EP262
Study Phase: Phase IIProduct Type: Small molecule
Recipient: Escient Pharmaceuticals
Deal Size: $750.0 million Upfront Cash: Undisclosed
Deal Type: Acquisition April 23, 2024
Lead Product(s) : EP262
Therapeutic Area : Dermatology
Highest Development Status : Phase II
Recipient : Escient Pharmaceuticals
Deal Size : $750.0 million
Deal Type : Acquisition
Incyte Acquires Escient Pharmaceuticals and Its Pipeline of Oral MRGPR Antagonists
Details : Incyte gains access to Escient's pipeline, including EP262, a selective small molecule antagonist of MRGPRX2 for atopic dermatitis.
Brand Name : EP262
Molecule Type : Small molecule
Upfront Cash : Undisclosed
April 23, 2024
Details:
CMS will be responsible for developing and commercializing INCB54707, it is being evaluated for non-segmental vitiligo, hidradenitis suppurativa, prurigo nodularis, asthma.
Lead Product(s): Povorcitinib
Therapeutic Area: Dermatology Brand Name: INCB054707
Study Phase: Phase IIIProduct Type: Small molecule
Sponsor: China Medical System Holdings Limited
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement April 01, 2024
Lead Product(s) : Povorcitinib
Therapeutic Area : Dermatology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : China Medical System Holdings Limited
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Incyte and Cms Announce Collaboration and License Agreement for Povorcitinib
Details : CMS will be responsible for developing and commercializing INCB54707, it is being evaluated for non-segmental vitiligo, hidradenitis suppurativa, prurigo nodularis, asthma.
Brand Name : INCB054707
Molecule Type : Small molecule
Upfront Cash : Undisclosed
April 01, 2024
Details:
INCB54707 (povorcitinib) is an oral small-molecule JAK1 inhibitor currently in Phase 2 clinical trial for adult patients with prurigo nodularis. A Phase 3 trial is being planned for prurigo nodularis.
Lead Product(s): Povorcitinib
Therapeutic Area: Dermatology Brand Name: INCB054707
Study Phase: Phase IIProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 10, 2024
Lead Product(s) : Povorcitinib
Therapeutic Area : Dermatology
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Incyte Presents New Late-Breaking Data from Phase 2 Evaluating Povorcitinib
Details : INCB54707 (povorcitinib) is an oral small-molecule JAK1 inhibitor currently in Phase 2 clinical trial for adult patients with prurigo nodularis. A Phase 3 trial is being planned for prurigo nodularis.
Brand Name : INCB054707
Molecule Type : Small molecule
Upfront Cash : Not Applicable
March 10, 2024
Details:
Opzelura (ruxolitinib phosphate), a topical JAK1/JAK2 inhibitor, is in phase 2 trials for treating mild-to-moderate hidradenitis suppurativa in adults.
Lead Product(s): Ruxolitinib Phosphate
Therapeutic Area: Dermatology Brand Name: Opzelura
Study Phase: Phase IIProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 10, 2024
Lead Product(s) : Ruxolitinib Phosphate
Therapeutic Area : Dermatology
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Incyte Announces New Data from Phase 2 Study Of Ruxolitinib Cream in Hidradenitis
Details : Opzelura (ruxolitinib phosphate), a topical JAK1/JAK2 inhibitor, is in phase 2 trials for treating mild-to-moderate hidradenitis suppurativa in adults.
Brand Name : Opzelura
Molecule Type : Small molecule
Upfront Cash : Not Applicable
March 10, 2024
Details:
INCA034176 (axatilimab) is an investigational monoclonal antibody that targets CSF-1R. It is bein evaluated for the treatment of chronic graft-versus-host disease.
Lead Product(s): Axatilimab
Therapeutic Area: Immunology Brand Name: INCA034176
Study Phase: Phase IIIProduct Type: Large molecule
Sponsor: Syndax Pharmaceuticals
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 27, 2024
Lead Product(s) : Axatilimab
Therapeutic Area : Immunology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Syndax Pharmaceuticals
Deal Size : Not Applicable
Deal Type : Not Applicable
Incyte Reports FDA Grants Priority Review for Axatilimab in Chronic GVHD
Details : INCA034176 (axatilimab) is an investigational monoclonal antibody that targets CSF-1R. It is bein evaluated for the treatment of chronic graft-versus-host disease.
Brand Name : INCA034176
Molecule Type : Large molecule
Upfront Cash : Not Applicable
February 27, 2024
Inspections and registrations
ABOUT THIS PAGE
LOOKING FOR A SUPPLIER?